http://www.nj.com/business/index.ssf/2012/08/bristol-myers_drug_flop_erases.html
if you make a multinational company lose a couple billion $ in short order & leave them stuck with trial deaths, AND expect anyone in the pharmaceutical industry ever to trust you again, you need to have your head examined imo. he's probably looking under his car every morning...
there's a really nice package deal available for you though from the experienced crew, if you're still game for it:
Synergy, $6 in January, now on sale at $1.90, Trovagene, went public at $24, now marked down to 51 cents for quick clearance, and ContraVir, $5 as recently as 2015, but now available for just 49 cents! Yes, you get all three of these made-to-be-sold companies for just $2.90! And, if you act now, we'll throw in 10 shares of Callisto Pharmaceuticals, a company which sank beneath the waves with Cap'n Gary at the helm!
"Enter through the narrow gate; for the gate is wide and the way is broad that leads to destruction, and there are many who enter through it. For the gate is small and the way is narrow that leads to life, and there are few who find it.”
Matthew 7:13-1
Recent IRWD News
- Ironwood Pharmaceuticals Announces Positive Results from its Phase II Exploratory STARGAZE Trial of Apraglutide in Patients with Steroid-Refractory Gastrointestinal Acute Graft-versus-Host Disease (SR GI aGVHD) • Business Wire • 03/28/2024 11:30:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/08/2024 09:05:19 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/07/2024 09:05:10 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/06/2024 09:05:12 PM
- Ironwood Pharmaceuticals Announces Positive Topline Results from Global Phase III Trial of Once-Weekly Apraglutide in Adults with Short Bowel Syndrome with Intestinal Failure (SBS-IF) • Business Wire • 02/29/2024 11:00:00 AM
- Ironwood Pharmaceuticals to Present Four Abstracts at the ASPEN 2024 Nutrition Science & Practice Conference • Business Wire • 02/23/2024 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/15/2024 12:04:58 PM
- Ironwood Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Results; Achieves 2023 Financial Guidance • Business Wire • 02/15/2024 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/15/2024 02:01:13 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/15/2024 01:53:45 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/15/2024 01:50:32 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/15/2024 01:42:46 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/15/2024 01:39:29 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/15/2024 01:35:15 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/12/2024 09:05:21 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 02/09/2024 09:13:58 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 02/09/2024 09:11:46 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 02/09/2024 09:09:12 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 02/09/2024 09:05:04 PM
- Ironwood Pharmaceuticals to Host Fourth Quarter and Full Year 2023 Investor Update Call • Business Wire • 02/01/2024 09:01:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/19/2024 09:05:33 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/19/2024 09:05:23 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/19/2024 09:05:19 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/19/2024 09:05:14 PM
- Ironwood Announces Publication in The Lancet Gastroenterology & Hepatology of New Linaclotide Phase III Data in Children and Adolescents Aged 6-17 Years with Functional Constipation • Business Wire • 01/09/2024 12:00:00 AM
VPR Brands LP Reports Record Annual Financial Performance for Fiscal Year 2023 • VPRB • Apr 19, 2024 11:24 AM
Coinllectibles' Subsidiary, Grand Town Development Limited, Acquires Rare Song Dynasty Ceramics Worth Over USD28million • COSG • Apr 18, 2024 8:03 AM
ILUS Provides Form 10-K Filing Update • ILUS • Apr 17, 2024 9:54 AM
Glucotrack Announces Expansion of Its Continuous Glucose Monitoring Technology to Epidural Glucose Monitoring • GCTK • Apr 17, 2024 8:00 AM
Maybacks Global Entertainment To Fire Up 24 New Stations in Louisiana • AHRO • Apr 16, 2024 1:30 PM
Cannabix Technologies Begins Certification of Contactless Alcohol Breathalyzer, Re-Brands product series to Breath Logix • BLOZF • Apr 16, 2024 8:52 AM